Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 in Advanced Esophageal Cancer
NCT05425472Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CPO-120 in esophageal cancer, sponsored by Hengrui. Primary endpoint: Objective Response Rate at 4 months. Status: unknown.
02
Drugs
CPO-120
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05425472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425472.